These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 10523804)
1. Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia. Hagberg H Med Oncol; 1999 Sep; 16(3):221-2. PubMed ID: 10523804 [TBL] [Abstract][Full Text] [Related]
2. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Hagberg H; Lundholm L Br J Haematol; 2001 Dec; 115(3):609-11. PubMed ID: 11736943 [TBL] [Abstract][Full Text] [Related]
3. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Hoffman M; Auerbach L Br J Haematol; 2000 Jun; 109(4):900-1. PubMed ID: 10970137 [No Abstract] [Full Text] [Related]
4. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report. Buckstein R; Patel H; Chesney A; Reis M; Imrie K Hematology; 2006 Aug; 11(4):267-70. PubMed ID: 17178666 [TBL] [Abstract][Full Text] [Related]
11. Rituximab in the treatment of the variant of hairy cell leukaemia: a case report. Hadzi-Pecova L; Stojanovik A; Petrusevska G; Panovska I Prilozi; 2008 Dec; 29(2):355-60. PubMed ID: 19259059 [TBL] [Abstract][Full Text] [Related]
12. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Zenhäusern R; Simcock M; Gratwohl A; Hess U; Bargetzi M; Tobler A; Haematologica; 2008 Sep; 93(9):1426-8. PubMed ID: 18603561 [No Abstract] [Full Text] [Related]
13. [Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant]. Telek B; Batár P; Udvardy M Orv Hetil; 2007 Sep; 148(38):1805-7. PubMed ID: 17872336 [TBL] [Abstract][Full Text] [Related]
14. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Quach H; Januszewicz H; Westerman D Haematologica; 2005 Nov; 90 Suppl():ECR26. PubMed ID: 16266917 [TBL] [Abstract][Full Text] [Related]
16. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. Imamura T; Ohtsuka E; Ogata M; Oka F; Kashima K; Kikuchi H; Nasu M Int J Hematol; 2004 Dec; 80(5):432-4. PubMed ID: 15646655 [TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of hairy-cell leukaemia. Mey U; Strehl J; Gorschlüter M; Ziske C; Glasmacher A; Pralle H; Schmidt-Wolf I Lancet Oncol; 2003 Feb; 4(2):86-94. PubMed ID: 12573350 [TBL] [Abstract][Full Text] [Related]
18. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063 [TBL] [Abstract][Full Text] [Related]
19. Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia. Forconi F; Toraldo F; Sozzi E; Amato T; Raspadori D; Lauria F Leuk Lymphoma; 2007 Dec; 48(12):2441-3. PubMed ID: 18067021 [No Abstract] [Full Text] [Related]
20. Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia. Vartholomatos G; Tsiara S; Christou L; Panteli A; Kaiafas P; Bourantas KL Acta Haematol; 1999; 102(2):94-8. PubMed ID: 10529513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]